Trial Outcomes & Findings for An Advanced Echocardiographic Evaluation of Nebivolol (NCT NCT01206439)
NCT ID: NCT01206439
Last Updated: 2018-02-15
Results Overview
Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.
Recruitment status
TERMINATED
Study phase
PHASE4
Target enrollment
2 participants
Primary outcome timeframe
Baseline to day 180
Results posted on
2018-02-15
Participant Flow
Participant milestones
| Measure |
Nebivolol 5 or 10 mg, Oral, Daily
Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily
|
|---|---|
|
Overall Study
STARTED
|
2
|
|
Overall Study
COMPLETED
|
1
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Nebivolol 5 or 10 mg, Oral, Daily
Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily
|
|---|---|
|
Overall Study
subject did not meet inclusion criteria
|
1
|
Baseline Characteristics
An Advanced Echocardiographic Evaluation of Nebivolol
Baseline characteristics by cohort
| Measure |
Nebivolol 5 or 10 mg, Oral, Daily
n=1 Participants
Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Baseline to day 180Population: Insufficient data to analyze.
Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline to day 180.Changes in exercise tolerance and time from baseline to 180 days.
Outcome measures
Outcome data not reported
Adverse Events
Nebivolol 5 or 10 mg, Oral, Daily
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place